Join
Live feed
·
NEWSReleasevia Quantisnow
ContraFect Corporation logo

ContraFect Has Received A Notice Of Allowance For Its U.S. Patent Application 16/629,916 Titled "Blood Component Potentiation Of Lytic Protein Anti-bacterial Activity And Methods And Uses Thereof"

ByQuantisnow·Wall Street's wire, on your screen.
CFRX· ContraFect Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CFRX (ContraFect Corporation) and more on Quantisnow.

ContraFect Has Received A Notice Of Allowance For Its U.S. Patent Application 16/629,916 Titled "Blood Component Potentiation Of Lytic Protein Anti-bacterial Activity And Methods And Uses Thereof" | Quantisnow